Skip to content
DraconiticResearch
Search Sources API
178,970 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BYCancers

Prediction of Response to Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

  • Mariana Verdelho Machado1,2,3
  1. 1Clínica Universitária de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal
  2. 2Unidade de Oncologia Digestiva, Fundação Champalimaud, 1400-038 Lisboa, Portugal
  3. 3Serviço de Gastrenterologia, Hospital de Vila Franca de Xira, 2600-009 Vila Franca de Xira, Portugal
Read full textPDFDOICite

Abstract

Worldwide, liver cancer is the seventh most common cancer and the third leading cause of cancer-related mortality, reflecting its dismal prognosis, with only approximately 20% of patients alive 5 years after diagnosis. At least 50% of patients ultimately require systemic treatment. In 2020, the systemic treatment landscape changed dramatically with the introduction of immune checkpoint inhibitor (ICI)-based therapies, which have demonstrated improved overall survival and longer preservation of quality of life compared with tyrosine kinase inhibitor (TKI)-based approaches. However, fewer than one third of patients achieve objective response, 10–25% experience severe immune-related adverse events, and ICI-based treatments represent a substantial economic burden for health systems. Importantly, robust and clinically validated predictive biomarkers of response to ICI remain an unmet need. This review summarizes current efforts to identify predictive biomarkers of ICI response in hepatocellular carcinoma (HCC), integrating clinical, pathological, molecular, microbiome, and imaging approaches, and discusses how these developments may shape the future of treatment selection.

Related

  1. Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy
    Jiangmin Zhou, Huifang Xiong, Honghao Zhou +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  2. Interpretable CT-Based Radiomics for Prediction of High-Affinity Neoantigens Associated Immunogenic States in Advanced Hepatocellular Carcinoma Treated with TACE Plus Targeted Therapy and Immunotherapy.
    Chaofan Bian, Yanjin Qin, Hongliang Zou +2
    CancersPeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMCCrossref
  3. Pathological complete response and major pathological response as surrogate endpoints for recurrence-free survival in perioperative immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis
    Xin Ai, Xiaoxiao Wang, Xin Wang +4
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  4. A PD‐L1 Nanobody‐Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC‐I
    Chuyu Huang, Yun Ye, Yi Guo +7
    ExplorationPeer-reviewedCC BY 4.0Full textOncologyPMC
  5. Multimodal biomarkers for early detection and immunotherapy assessment in hepatocellular carcinoma: integrating liquid biopsy, AI-based imaging and tumor immune profiling.
    Yuli Zhao, Xiaolei Chen, Hanyu Zhao
    Frontiers in geneticsPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{machado2026prediction,
  title = {{Prediction of Response to Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?}},
  author = {Mariana Verdelho Machado},
  journal = {Cancers},
  year = {2026},
  month = oct,
  doi = {10.3390/cancers18193167},
  url = {https://europepmc.org/article/PMC/PMC13663966},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Prediction of Response to Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
AU  - Mariana Verdelho Machado
PY  - 2026
DA  - 2026/10/01
JO  - Cancers
DO  - 10.3390/cancers18193167
UR  - https://europepmc.org/article/PMC/PMC13663966
AB  - Worldwide, liver cancer is the seventh most common cancer and the third leading cause of cancer-related mortality, reflecting its dismal prognosis, with only approximately 20% of patients alive 5 years after diagnosis. At least 50% of patients ultimately require systemic treatment. In 2020, the systemic treatment landscape changed dramatically with the introduction of immune checkpoint inhibitor (ICI)-based therapies, which have demonstrated improved overall survival and longer preservation of quality of life compared with tyrosine kinase inhibitor (TKI)-based approaches. However, fewer than one third of patients achieve objective response, 10–25% experience severe immune-related adverse events, and ICI-based treatments represent a substantial economic burden for health systems. Importantly, robust and clinically validated predictive biomarkers of response to ICI remain an unmet need. This review summarizes current efforts to identify predictive biomarkers of ICI response in hepatocellular carcinoma (HCC), integrating clinical, pathological, molecular, microbiome, and imaging approaches, and discusses how these developments may shape the future of treatment selection.
SN  - 2072-6694
ER  -